CA2256592A1 - Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent - Google Patents
Improved methods for diagnostic imaging by regulating the administration rate of a contrast agentInfo
- Publication number
- CA2256592A1 CA2256592A1 CA002256592A CA2256592A CA2256592A1 CA 2256592 A1 CA2256592 A1 CA 2256592A1 CA 002256592 A CA002256592 A CA 002256592A CA 2256592 A CA2256592 A CA 2256592A CA 2256592 A1 CA2256592 A1 CA 2256592A1
- Authority
- CA
- Canada
- Prior art keywords
- gas
- lipid
- gaseous precursor
- composition
- vesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract 362
- 238000002059 diagnostic imaging Methods 0.000 title claims abstract 26
- 239000002872 contrast media Substances 0.000 title claims abstract 25
- 230000001105 regulatory effect Effects 0.000 title claims 2
- 150000002632 lipids Chemical class 0.000 claims abstract 139
- 239000000203 mixture Substances 0.000 claims abstract 130
- 239000002243 precursor Substances 0.000 claims abstract 116
- 229920000642 polymer Polymers 0.000 claims abstract 50
- 239000008365 aqueous carrier Substances 0.000 claims abstract 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract 16
- 238000002604 ultrasonography Methods 0.000 claims abstract 5
- 239000007789 gas Substances 0.000 claims 168
- 150000003904 phospholipids Chemical class 0.000 claims 76
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 66
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims 52
- 229960004065 perflutren Drugs 0.000 claims 52
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 48
- 229910052757 nitrogen Inorganic materials 0.000 claims 36
- 229960004692 perflenapent Drugs 0.000 claims 36
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims 36
- 229960004624 perflexane Drugs 0.000 claims 32
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims 32
- 229910018503 SF6 Inorganic materials 0.000 claims 30
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims 30
- 229960000909 sulfur hexafluoride Drugs 0.000 claims 30
- -1 N-substituted acrylamides Chemical class 0.000 claims 27
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims 20
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 claims 20
- 235000019407 octafluorocyclobutane Nutrition 0.000 claims 20
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims 20
- 229950003332 perflubutane Drugs 0.000 claims 20
- UVWPNDVAQBNQBG-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-icosafluorononane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UVWPNDVAQBNQBG-UHFFFAOYSA-N 0.000 claims 18
- PWMJXZJISGDARB-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5-decafluorocyclopentane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F PWMJXZJISGDARB-UHFFFAOYSA-N 0.000 claims 18
- GQUXQQYWQKRCPL-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluorocyclopropane Chemical compound FC1(F)C(F)(F)C1(F)F GQUXQQYWQKRCPL-UHFFFAOYSA-N 0.000 claims 18
- LGUZHRODIJCVOC-UHFFFAOYSA-N perfluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F LGUZHRODIJCVOC-UHFFFAOYSA-N 0.000 claims 18
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 claims 18
- 238000011010 flushing procedure Methods 0.000 claims 14
- 150000004676 glycans Chemical class 0.000 claims 12
- 230000001939 inductive effect Effects 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 239000005017 polysaccharide Substances 0.000 claims 12
- 229920001282 polysaccharide Polymers 0.000 claims 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 11
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 11
- 239000004094 surface-active agent Substances 0.000 claims 10
- 229920001651 Cyanoacrylate Polymers 0.000 claims 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 9
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 9
- 229920002239 polyacrylonitrile Polymers 0.000 claims 9
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 8
- 239000002356 single layer Substances 0.000 claims 8
- 238000012285 ultrasound imaging Methods 0.000 claims 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 6
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 6
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 6
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- 229910001873 dinitrogen Inorganic materials 0.000 claims 6
- 229930182830 galactose Natural products 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 6
- 239000004926 polymethyl methacrylate Substances 0.000 claims 6
- 229920001059 synthetic polymer Polymers 0.000 claims 6
- 239000002691 unilamellar liposome Substances 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 210000004204 blood vessel Anatomy 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000002502 liposome Substances 0.000 claims 5
- 239000000693 micelle Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000013170 computed tomography imaging Methods 0.000 claims 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims 4
- ACZNIBVNGPLHAC-ONEGZZNKSA-N (2e)-penta-2,4-dien-1-ol Chemical compound OC\C=C\C=C ACZNIBVNGPLHAC-ONEGZZNKSA-N 0.000 claims 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 3
- QLIBJPGWWSHWBF-UHFFFAOYSA-N 2-aminoethyl methacrylate Chemical class CC(=C)C(=O)OCCN QLIBJPGWWSHWBF-UHFFFAOYSA-N 0.000 claims 3
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 3
- XTHDRUMOXKOSLN-UHFFFAOYSA-N 4-(3-phenylprop-1-enyl)aniline Chemical compound C1=CC(N)=CC=C1C=CCC1=CC=CC=C1 XTHDRUMOXKOSLN-UHFFFAOYSA-N 0.000 claims 3
- LBSXSAXOLABXMF-UHFFFAOYSA-N 4-Vinylaniline Chemical compound NC1=CC=C(C=C)C=C1 LBSXSAXOLABXMF-UHFFFAOYSA-N 0.000 claims 3
- YFGSHAIDEAXREE-UHFFFAOYSA-N 6,6-dimethyl-1,3,5,2,4-trioxadisilepane Chemical compound CC1(C)CO[SiH2]O[SiH2]O1 YFGSHAIDEAXREE-UHFFFAOYSA-N 0.000 claims 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 3
- 239000004952 Polyamide Substances 0.000 claims 3
- 229920002873 Polyethylenimine Polymers 0.000 claims 3
- 229920002125 Sokalan® Polymers 0.000 claims 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 3
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 3
- 239000003822 epoxy resin Substances 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims 3
- 239000004584 polyacrylic acid Substances 0.000 claims 3
- 229920002647 polyamide Polymers 0.000 claims 3
- 229920000647 polyepoxide Polymers 0.000 claims 3
- 239000004626 polylactic acid Substances 0.000 claims 3
- 229920001296 polysiloxane Polymers 0.000 claims 3
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 claims 3
- BUJXOJKSMCPEEB-UHFFFAOYSA-N sodium;2-sulfooxyethyl 2-methylprop-2-enoate Chemical compound [Na].CC(=C)C(=O)OCCOS(O)(=O)=O BUJXOJKSMCPEEB-UHFFFAOYSA-N 0.000 claims 3
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 238000009835 boiling Methods 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/928—X-ray agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/929—Ultrasound contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/93—MRI contrast agent
Abstract
Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region.
The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
Claims (411)
1. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said vesicle composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in the image.
2. A method according to Claim 1 wherein said vesicles comprise lipids.
3. A method according to Claim 2 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.
4. A method according to Claim 2 wherein said lipids comprise phospholipids.
5. A method according to Claim 4 wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.
6. A method according to Claim 5 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
7. A method according to Claim 6 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.
8. A method according to Claim 5 wherein said phosphatidylethanolamine, is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoylphosphatidylethanolamine and1-hexadecyl-2-palmitoylglycerophosphoethanolamine.
9. A method according to Claim 8 wherein said phosphatidylethanolamine, comprises dipalmitoylphosphatidylethanolamine.
10. A method according to Claim 5 wherein said phosphatidic acid comprises dipalmitolylphosphatidic acid.
11. A method according to Claim 2 wherein said lipid further comprises a polymer.
12. A contrast agent according to Claim 11 wherein said polymer comprises a hydrophilic polymer.
13. A method according to Claim 11 wherein said hydrophilic polymer comprises polyethylene glycol.
14. A method according to Claim 1 wherein said vesicles comprise proteins.
15. A method according to Claim 14 wherein said proteins comprise albumin.
16. A method according to Claim 1 wherein said vesicles comprise polymers.
17. A method according to Claim 16 wherein said polymers comprise synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, .epsilon.-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-aminostyrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethylmethacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.
18. A method according to Claim 16 wherein said polymers comprise synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(.epsilon.-caprolactone), epoxy resin, poly(ethylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethylmethacrylate and polystyrene-polyacrylonitrile.
19. A method according to Claim 18 wherein said polymers comprise polyvinylidene-polyacrylonitrile copolymer.
20. A method according to Claim 1 wherein said gas comprises a fluorinated gas.
21. A method according to Claim 20 wherein said fluorinated gas is selected from the group consisting of a perfluorocarbon, sulfur hexafluoride andheptafluoropropane.
22. A method according to Claim 21 wherein said fluorinated gas comprises a perfluorocarbon.
23. A method according to Claim 22 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.
24. A method according to Claim 1 wherein said gaseous precursor has a boiling point of greater than about 37°C.
25. A method according to Claim 24 wherein said gaseous precursor comprises a fluorinated compound.
26. A method according to Claim 25 wherein said fluorinated compound comprises a perfluorocarbon.
27. A method according to Claim 26 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane and perfluorohexane.
28. A method according to Claim 1 wherein said diagnostic imaging is selected from the group consisting of ultrasound imaging and computed tomographyimaging.
29. A method according to Claim 28 wherein said diagnostic imaging comprises ultrasound imaging.
30. A method according to Claim 1 wherein said internal region comprises the heart region.
31. A method according to Claim 1 wherein said vesicle composition is administered to the patient at a rate of from about 1 x 10 6 to less than about 8 x 10 6 vesicles/Kg-sec.
32. A method according to Claim 31 wherein said vesicle composition is administered at a rate of from about 1 x 10 6 to about 7 x 10 6 vesicles/Kg-sec.
33. A method according to Claim 32 wherein said vesicle composition is administered at a rate of from about 1.5 x 10 6 to about 6 x 10 6 vesicles/Kg-sec.
34. A method according to Claim 33 wherein said vesicle composition is administered at a rate of from about 2 x 10 6 to about 5.5 x 10 6 vesicles/Kg-sec.
35. A method according to Claim 34 wherein said vesicle composition is administered at a rate of from about 2.5 x 10 6 to about 5 x 10 6 vesicles/Kg-sec.
36. A method according to Claim 35 wherein said vesicle composition is administered at a rate of from about 3 x 10 6 to about 4.5 x 10 6 vesicles/Kg-sec.
37. A method according to Claim 1 wherein said vesicle composition is administered to the patient at a rate of from about 1 x 10-7 to about 3 x 10-3 CC gas/Kg-sec.
38. A method according to Claim 37 wherein said vesicle composition is administered at a rate of from about 3 x 10-6 to about 3 x 10-3 cc gas/Kg-sec.
39. A method according to Claim 38 wherein said vesicle composition is administered at a rate of from about 4 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
40. A method according to Claim 39 wherein said vesicle composition is administered at a rate of from about 8 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
41. A method according to Claim 40 wherein said vesicle composition is administered at a rate of from about 1 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
42. A method according to Claim 41 wherein said vesicle composition is administered at a rate of from about 4 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
43. A method according to Claim 42 wherein said vesicle composition is administered at a rate of from about 8 x 10-5 to less than about 1 x 10-3 cc gas/Kg-sec.
44. A method according to Claim 43 wherein said vesicle composition is administered at a rate of from about 1 x 10-4 to about 9 x 10-4 cc gas/Kg-sec.
45. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a lipid composition comprising, in an aqueous carrier, a lipid and a gas or gaseous precursor, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said lipid composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in the image.
46. A method according to Claim 43 wherein said lipid comprises a phospholipid.
47. A method according to Claim 46 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.
48. A method according to Claim 47 wherein said lipid composition comprises a vesicle composition.
49. A method according to Claim 48 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.
50. A method according to Claim 45 wherein said diagnostic imaging is selected from the group consisting of ultrasound imaging and computed tomographyimaging.
51. A method according to Claim 50 wherein said diagnostic imaging comprises ultrasound imaging.
52. A method according to Claim 45 wherein said lipid composition is administered to the patient at a rate of from about 1 x 10-7 to about 3 x 10-3 cc gas/Kg-sec.
53. A method according to Claim 52 wherein said lipid composition is administered at a rate of from about 3 x 10-6 to about 3 x 10-3 cc gas/Kg-sec.
54. A method according to Claim 53 wherein said lipid composition is administered at a rate of from about 4 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
55. A method according to Claim 54 wherein said lipid composition is administered at a rate of from about 8 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
56. A method according to Claim 55 wherein said lipid composition is administered at a rate of from about 1 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
57. A method according to Claim 56 wherein said lipid composition is administered at a rate of from about 4 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
58. A method according to Claim 57 wherein said lipid composition is administered at a rate of from about 8 x 10-5 to less than about 1 x 10-3 cc gas/Kg-sec.
59. A method according to Claim 58 wherein said lipid composition is administered at a rate of from about 1 x 10-4 to about 9 x 10-4 cc gas/Kg-sec.
60. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
61. A method accroding to Claim 60 wherien said vesicles comprise lipids.
62. A method according to Claim 60 wherein said lipids comprise phospholipids.
63. A method according to Claim 62 wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.
64. A method according to Claim 63 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
65. A method according to Claim 64 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.
66. A method according to Claim 63 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoylphosphatidylethanolamine and1-hexadecyl-2-palmitoylglycerophosphoethanolamine..
67. A method according to Claim 66 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.
68. A method according to Claim 63 wherein said phosphatidic acid comprises dipalmitolylphosphatidic acid.
69. A method according to Claim 60 wherein said vesicles comprise proteins.
70. A method according to Claim 69 wherein said proteins comprise albumin.
71. A method according to Claim 60 wherein said vesicles comprise polymers.
72. A method according to Claim 71 wherein said polymers comprise synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, .epsilon.-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethylmethacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethylammonium chloride.
73. A method according to Claim 71 wherein said polymers comprise synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(.epsilon.-caprolactone), epoxy resin, poly(ethylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethylmethacrylate and polystyrene-polyacrylonitrile.
74. A method according to Claim 73 wherein said polymers comprise polyvinylidene-polyacrylonitrile copolymer.
75. A method according to Claim 60 wherein said vesicle composition is flushed with a saline solution.
76. A method according to Claim 60 wherein said gas comprises a fluorinated gas.
77. A method according to Claim 76 wherein said fluorinated gas is selected from the group consisting of a perfluorocarbon gas, sulfur hexafluoride and heptafluoropropane.
78. A method according to Claim 77 wherein said fluorinated gas comprises a perfluorocarbon.
79. A method according to Claim 78 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.
80. A method according to Claim 60 wherein said gaseous precursor has a boiling point of greater than about 37°C.
81. A method according to Claim 80 wherein said gaseous precursor comprises a fluorinated compound.
82. A method according to Claim 81 wherein said fluorinated compound comprises a perfluorocarbon.
83. A method according to Claim 82 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane and perfluorohexane.
84. A method according to Claim 61 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.
85. A method according to Claim 60 wherein said diagnostic imaging is selected from the group consisting of ultrasound imaging and computed tomographyimaging.
86. A method according to Claim 85 wherein said diagnostic imaging comprises ultrasound imaging.
87. A method according to Claim 60 wherein said internal region comprises the heart region.
88. A method according to Claim 60 wherein said vesicle composition is flushed at a rate of from about 0.01 to about 2.4 mL/sec.
89. A method according to Claim 88 wherein said vesicle composition is flushed at a rate of from about 0.05 to about 2 mL/sec.
90. A method according to Claim 89 wherein said vesicle composition is flushed at a rate of from about 0.07 to about 1.8 mL/sec.
91. A method according to Claim 90 wherein said vesicle composition is flushed at a rate of from about 0.09 to about 1.6 mL/sec.
92. A method according to Claim 91 wherein said vesicle composition is flushed at a rate of from about 0.1 to about 1.5 mL/sec.
93. A method according to Claim 92 wherein said vesicle composition is flushed at a rate of from about 0.3 to about 1.3 mL/sec.
94. A method according to Claim 93 wherein said vesicle composition is flushed at a rate of from about 0.5 to about 1.1 mL/sec.
95. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a lipid composition comprising, in an aqueous carrier, a lipid and a gas or gaseous precursor, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
96. A method according to Claim 95 wherein said lipid comprises a phospholipid.
97. A method according to Claim 96 wherein said phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.
98. A method according to Claim 97 wherein said lipid composition comprises a vesicle composition.
99. A method according to Claim 95 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.
100. A method according to Claim 95 wherein said diagnostic imaging is selected from the group consisting of ultrasound imaging and computed tomographyimaging.
101. A method according to Claim 90 wherein said diagnostic imaging comprises ultrasound imaging.
102. A method according to Claim 95 wherein said internal region comprises the heart region.
103. A method according to Claim 95 wherein said composition is flushed at a rate of from about 0.01 to about 2.4 mL/sec.
104. A method according to Claim 103 wherein said lipid composition is flushed at a rate of from about 0.05 to about 2 mL/sec.
105. A method according to Claim 104 wherein said lipid composition is flushed at a rate of from about 0.07 to about 1.8 mL/sec.
106. A method according to Claim 105 wherein said lipid composition is flushed at a rate of from about 0.09 to about 1.6 mL/sec.
107. A method according to Claim 106 wherein said lipid composition is flushed at a rate of from about 0.1 to about 1.5 mL/sec.
108. A method according to Claim 107 wherein said lipid composition is flushed at a rate of from about 0.3 to about 1.3 mL/sec.
109. A method according to Claim 108 wherein said lipid composition is flushed at a rate of from about 0.5 to about 1.1 mL/sec.
110. A method for substantially eliminating diagnostic artifacts in a diagnostic image of an internal region of a patient comprising regulating the rate at which a contrast agent is administered to the patient.
111. A method according to Claim 110 wherein the diagnostic image is selected from the group consisting of ultrasound images and computed tomography images.
112. A method according to Claim 111 wherein the diagnostic image comprises ultrasound images.
113. A method according to Claim 110 wherein the diagnostic artifacts are selected from the group consisting of ultrasound artifacts and computed tomography artifacts.
114. A method according to Claim 113 wherein the diagnostic artifacts comprise ultrasound artifacts.
115. A method according to Claim 110 wherein said contrast agent comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers.
116. A method according to Claim 115 wherein said vesicles comprise lipids.
117. A method according to Claim 116 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.
118. A method according to Claim 116 wherein said lipids comprise phospholipids.
119. A method according to Claim 118 wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.
120. A method according to Claim 119 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
121. A method according to Claim 120 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.
122. A method according to Claim 119 wherein said phosphatidyl-ethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanol-amine, dioleoylphosphatidylethanolamine, N-succinyldioleoylphosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.
123. A method according to Claim 122 wherein said phosphatidylethanolamine comprises dipalmitoylphosphatidylethanolamine.
124. A method according to Claim 119 wherein said phosphatidic acid comprises dipalmitolylphosphatidic acid.
125. A method according to Claim 116 wherein said lipid further comprises a polymer.
126. A contrast agent according to Claim 125 wherein said polymer comprises a hydrophilic polymer.
127. A method according to Claim 126 wherein said hydrophilic polymer comprises polyethylene glycol.
128. A method according to Claim 115 wherein said vesicles comprise proteins.
129. A method according to Claim 128 wherein said proteins comprise albumin.
130. A method according to Claim 115 wherein said vesicles comprise polymers.
131. A method according to Claim 130 wherein said polymers comprise synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl methacrylate, lactic acid, glycolic acid, .epsilon.-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.
132. A method according to Claim 130 wherein said polymers comprise synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(.epsilon.-caprolactone), epoxy resin, poly(ethylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethylmethacrylate and polystyrene-polyacrylonitrile.
133. A method according to Claim 132 wherein said polymers comprise polyvinylidene-polyacrylonitrile copolymer.
134. A method according to Claim 115 wherein said vesicle composition is administered to the patient at a rate of from about 1 x 10 6 to less than about 8 x 10 6 vesicles/Kg-sec.
135. A method according to Claim 134 wherein said vesicle composition is administered at a rate of from about 1 x 10 6 to about 7 x 10 6 vesicles/Kg-sec.
136 A method according to Claim 135 wherein said vesicle composition is administered at a rate of from about 1.5 x 10 6 to about 6 x 10 6 vesicles/Kg-sec.
137. A method according to Claim 136 wherein said vesicle composition is administered at a rate of from about 2 x 10 6 to about 5.5 x 10 6 vesicles/Kg-sec.
138. A method according to Claim 137 wherein said vesicle composition is administered at a rate of from about 2.5 x 10 6 to about 5 x 10 6 vesicles/Kg-sec.
139. A method according to Claim 138 wherein said vesicle composition is administered at a rate of from about 3 x 10 6 to about 4.5 x 10 6 vesicles/Kg-sec.
140. A method according to Claim 115 wherein said vesicle composition is administered to the patient at a rate of from about 1 x 10-7 to about 3 x 10-3 cc gas/Kg-sec.
141. A method according to Claim 140 wherein said vesicle composition is administered at a rate of from about 3 x 10-6 to about 3 x 10-3 cc gas/Kg-sec.
142. A method according to Claim 141 wherein said vesicle composition is administered at a rate of from about 4 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
143. A method according to Claim 142 wherein said vesicle composition is administered at a rate of from about 8 x 10-6 to about 2 x 10-3 cc gas/Kg-sec.
144. A method according to Claim 143 wherein said vesicle composition is administered at a rate of from about 1 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
145. A method according to Claim 144 wherein said vesicle composition is administered at a rate of from about 4 x 10-5 to about 1 x 10-3 cc gas/Kg-sec.
146. A method according to Claim 145 wherein said vesicle composition is administered at a rate of from about 8 x 10-5 to less than about 1 x 10-3 cc gas/Kg-sec.
147. A method according to Claim 146 wherein said vesicle composition is administered at a rate of from about 1 x 10-4 to about 9 x 10-4 cc gas/Kg-sec.
148. A method according to Claim 100 wherein said administration also comprises flushing said contrast agent.
149. A method according to Claim 148 wherein said contrast agent is flushed at a rate of administered to the patient at a rate of from about 1 x 10-7 to about 3 x 10-3 cc gas/Kg-sec.
150. A method according to Claim 149 wherein said contrast agent is flushed at a rate of from about 0.05 to about 2 mL/sec.
151. A method according to Claim 150 wherein said contrast agent is flushed at a rate of from about 0.07 to about 1.8 mL/sec.
152. A method according to Claim 151 wherein said contrast agent is flushed at a rate of from about 0.09 to about 1.6 mL/sec.
153. A method according to Claim 152 wherein said contrast agent is flushed at a rate of from about 0.1 to about 1.5 mL/sec.
154. A method according to Claim 153 wherein said contrast agent is flushed at a rate of from about 0.3 to about 1.3 mL/sec.
155. A method according to Claim 154 wherein said contrast agent is flushed at a rate of from about 0.5 to about 1.1 mL/sec.
156. A method according to Claim 100 wherein the region comprises the heart region.
157. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said vesicle composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in said image.
158. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a lipid composition comprising, in an aqueous carrier, a lipid and a gas or gaseous precursor, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said lipid composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in said image.
159. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said vesicle composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
160. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a lipid composition comprising. in an aqueous carrier, a lipid and a gas or gaseous precursor, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said lipid composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
161. A system for administering a contrast agent to a patient comprising:
(a) a first vessel containing a contrast agent;
(b) a second vessel containing a flushing agent;
(c) a conduit having means for directing fluid into a blood vessel of the patient;
(d) means for placing said first and second vessels into flow communication with said conduit;
(e) first flow inducing means for inducing said contrast agent to flow from said first vessel into said conduit; and (f) second flow inducing means for inducing said flushing agent to flow from said second vessel into said conduit subsequent to said flowing of said contrast agent into said conduit by said first flow inducing means.
(a) a first vessel containing a contrast agent;
(b) a second vessel containing a flushing agent;
(c) a conduit having means for directing fluid into a blood vessel of the patient;
(d) means for placing said first and second vessels into flow communication with said conduit;
(e) first flow inducing means for inducing said contrast agent to flow from said first vessel into said conduit; and (f) second flow inducing means for inducing said flushing agent to flow from said second vessel into said conduit subsequent to said flowing of said contrast agent into said conduit by said first flow inducing means.
162. A system according to Claim 161 wherein said second flow inducing means further comprises means for inducing said contrast agent to flow from said conduit into said blood vessel and for subsequently inducing said flushing agent to flow from said conduit into said blood vessel.
163. A system according to Claim 162 wherein said second flow inducing means has means for inducing flow at variable rates, whereby said contrast agent flows into said blood vessel at a first rate and said flushing agent flows into said blood vessel at a second rate.
164. A system according to Claim 161 wherein said first flow inducing means comprises a syringe plunger and said first vessel comprises a syringe barrel in which said plunger slides.
165. A system according to Claim 161 wherein said second flow inducing means comprises a mechanical injector.
166. A system according to Claim 165 wherein said mechanical injector operates using pneumatic or hydraulic pressure.
167. A system according to Claim 161 wherein said conduit comprises a needle.
168. A system according to Claim 161 wherein said conduit comprises tubing.
169. A system according to Claim 161 wherein said means for placing said first and second vessels into flow communication with said conduit comprises a three-way stopcock.
170. A system according to Claim 161 wherein said means for placing said first and second vessels into flow communication with said conduit comprises a port.
171. A system according to Claim 161 wherein said contrast agent comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers.
172. A system according to Claim 161 wherein said contrast agent comprises a lipid composition comprising, in an aqueous carrier, a lipid and a gas or gaseous precursor.
173. A system according to Claim 161 wherein said flushing agent comprises a saline solution.
174. A method according to Claim 2 wherein said vesicles comprise lipid-coated bubbles.
175. A method according to Claim 174 wherein said vesicles are selected from the group consisting of unilamellar vesicles, oligolamellar vesicles and multilamellar vesicles.
176. A method according to Claim 175 wherein said vesicles comprise unilamellar vesicles.
177. A method according to Claim 176 wherein said vesicles comprise one monolayer.
178. A method according to Claim 177 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
179. A method according to Claim 177 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
180. A method according to Claim 177 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
181. A method according to Claim 176 wherein said vesicles comprise one bilayer.
182. A method according to Claim 181 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
183. A method according to Claim 181 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
184. A method according to Claim 181 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
185. A method according to Claim 175 wherein said vesicles are selected from the group consisting of oligolamellar vesicles and multilamellar vesicles.
186. A method according to Claim 185 wherein said vesicles comprise one monolayer.
187. A method according to Claim 186 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
188. A method according to Claim 186 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
189. A method according to Claim 186 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
190. A method according to Claim 185 wherein said vesicles comprise one bilayer.
191. A method according to Claim 190 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
192. A method according to Claim 190 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
193. A method according to Claim 190 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
194. A method according to Claim 45 wherein said lipid is selected from the group consisting of unilamellar lipids, oligolamellar lipids or multilamellar lipids.
195. A method according to Claim 194 wherein said lipid is a unilamellar lipid.
196. A method according to Claim 195 wherein said unilamellar lipid comprises one monolayer.
197. A method according to Claim 196 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
198. A method according to Claim 196 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
199. A method according to Claim 196 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
200. A method according to Claim 196 wherein said lipid comprises one bilayer.
201. A method according to Claim 200 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
202. A method according to Claim 200 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
203. A method according to Claim 200 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
204. A method according to Claim 194 wherein said lipid is selected from the group consisting of oligolamellar lipids and multilamellar lipids.
205. A method according to Claim 204 wherein said lipid comprises one monolayer.
206. A method according to Claim 205 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
207. A method according to Claim 205 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
208. A method according to Claim 205 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
209. A method according to Claim 204 wherein said lipid comprises one bilayer.
210. A method according to Claim 209 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
211. A method according to Claim 209 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
212. A method according to Claim 209 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
213. A method according to Claim 60 wherein said vesicles comprise lipid-coated bubbles.
214. A method according to Claim 213 wherein said vesicles are selected from the group consisting of unilamellar vesicles, oligolamellar vesicles and multilamellar vesicles.
215. A method according to Claim 214 wherein said lipids comprise a phospholipid.
216. A method according to Claim 214 wherein said vesicles comprise unilamellar vesicles.
217. A method according to Claim 216 wherein said vesicles comprise one monolayer.
218. A method according to Claim 216 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
219. A method according to Claim 216 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
220. A method according to Claim 216 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
221. A method according to Claim 216 wherein said vesicles comprise one bilayer.
222. A method according to Claim 221 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
223. A method according to Claim 221 wherein said lipid is a phospholipid and said gaseous precursor is perfluoropentane.
224. A method according to Claim 221 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
225. A method according to Claim 214 wherein said vesicles are selected from the group consisting of oligolamellar vesicles and multilamellar vesicles.
226. A method according to Claim 225 wherein said vesicles comprise one monolayer.
227. A method according to Claim 226 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
228. A method according to Claim 226 wherein said lipid is a phospholipid and said gaseous precursor is perfluoropentane.
229. A method according to Claim 226 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
230. A method according to Claim 225 wherein said vesicles comprise one bilayer.
231. A method according to Claim 230 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
232. A method according to Claim 230 wherein said lipid is a phospholipid and said gaseous precursor is perfluoropentane.
233. A method according to Claim 230 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
234. A system according to Claim 171 wherein said vesicles comprise lipid vesicles.
235. A system according to Claim 234 wherein said vesicles comprise lipid-coated bubbles.
236. A system according to Claim 234 wherein said vesicles are selected from the group consisting of unilamellar vesicles, oligolamellar vesicles and multilamellar vesicles.
237. A system according to Claim 236 wherein said vesicles comprise unilamellar vesicles.
238. A system according to Claim 237 wherein said vesicles comprise one monolayer.
239. A system according to Claim 238 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
240. A system according to Claim 238 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
241. A method according to Claim 238 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
242. A system according to Claim 237 wherein said vesicles comprise one bilayer.
243. A system according to Claim 242 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
244. A system according to Claim 242 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
245. A system according to Claim 242 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
246. A system according to Claim 236 wherein said vesicles are selected from the group consisting of oligolamellar vesicles and multilamellar vesicles.
247. A system according to Claim 246 wherein said vesicles comprise one monolayer.
248. A system according to Claim 247 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
249. A system according to Claim 247 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
250. A system according to Claim 248 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
251. A system according to Claim 246 wherein said vesicles comprise one bilayer.
252. A system according to Claim 251 wherein said lipid is a phospholipid and said gas or gaseous precursor is sulfur hexafluoride.
253. A system according to Claim 251 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropentane.
254. A method according to Claim 251 wherein said lipid is a phospholipid and said gas or gaseous precursor is perfluoropropane.
255. A method according to Claim 174 wherein said lipid is a polymerized lipid.
256. A method according to Claim 174 wherein said vesicles further comprise polyethylene glycol.
257. A method according to Claim 213 wherein said lipid is a polymerized lipid.
258. A method according to Claim 213 wherein said vesicles further comprise polyethylene glycol.
259. A system according to Claim 234 wherein said lipid is a polymerized lipid.
260. A system according to Claim 234 wherein said vesicles further comprise polyethylene glycol.
261. A method according to Claim 16 wherein said polymer comprises a polysaccharide.
262. A method according to Claim 261 wherein said polysaccharide comprises galactose.
263. A method according to Claim 261 wherein said gas is nitrogen gas.
264. A method according to Claim 71 wherein said polymer comprises a polysaccharide.
265. A method according to Claim 264 wherein said polysaccharide comprises galactose.
266. A method according to Claim 264 wherein said gas is nitrogen gas.
267. A method according to Claim 130 wherein said polymer comprises a polysaccharide.
268. A method according to Claim 267 wherein said polysaccharide comprises galactose.
269. A method according to Claim 267 wherein said gas is nitrogen gas.
270. A method according to Claim 157 wherein said vesicles comprise polymers.
271. A method according to Claim 270 wherein said polymer comprises a polysaccharide.
272. A method according to Claim 271 wherein said polysaccharide comprises galactose.
273. A method according to Claim 271 wherein said gas is nitrogen gas.
274. A method according to Claim 159 wherein said vesicles comprise polymers.
275. A method according to Claim 274 wherein said polymer comprises a polysaccharide.
276. A method according to Claim 275 wherein said polysaccharide comprises galactose.
277. A method according to Claim 275 wherein said gas is nitrogen gas.
278. A method according to Claim 171 wherein said vesicles comprise polymers.
279. A method according to Claim 278 wherein said polymer comprises a polysaccharide.
280. A method according to Claim 279 wherein said polysaccharide comprises galactose.
281. A method according to Claim 279 wherein said gas is nitrogen gas.
282. A method according to Claim 17 wherein said polymer comprises an acrylate.
283. A method according to Claim 282 wherein said gas is air.
284. A method according to Claim 17 wherein said polymer comprises a methacrylate.
285. A method according to Claim 284 wherein said gas is air.
286. A method according to Claim 17 wherein said polymer comprises a cyanoacrylate.
287. A method according to Claim 286 wherein said gas is air.
288. A method according to Claim 72 wherein said polymer comprises an acrylate.
289. A method according to Claim 288 wherein said gas is air.
290. A method according to Claim 72 wherein said polymer comprises a methacrylate.
291. A method according to Claim 290 wherein said gas is air.
292. A method according to Claim 72 wherein said polymer comprises a cyanoacrylate.
293. A method according to Claim 292 wherein said gas is air.
294. A method according to Claim 131 wherein said polymer comprises an acrylate.
295. A method according to Claim 294 wherein said gas is air.
296. A method according to Claim 131 wherein said polymer comprises a methacrylate.
297. A method according to Claim 296 wherein said gas is air.
298. A method according to Claim 131 wherein said polymer comprises a cyanoacrylate.
299. A method according to Claim 298 wherein said gas is air.
300. A method according to Claim 270 wherein said polymer comprises an acrylate.
301. A method according to Claim 300 wherein said gas is air.
302. A method according to Claim 270 wherein said polymer comprises a methacrylate.
303. A method according to Claim 302 wherein said gas is air.
304. A method according to Claim 270 wherein said polymer comprises a cyanoacrylate.
305. A method according to Claim 304 wherein said gas is air.
306. A method according to Claim 274 wherein said polymer comprises an acrylate.
307. A method according to Claim 306 wherein said gas is air.
308. A method according to Claim 274 wherein said polymer comprises a methacrylate.
309. A method according to Claim 308 wherein said gas is air.
310. A method according to Claim 274 wherein said polymer comprises a cyanoacrylate.
311. A method according to Claim 310 wherein said gas is air.
312. A method according to Claim 278 wherein said polymer comprises an acrylate.
313. A method according to Claim 312 wherein said gas is air.
314. A method according to Claim 278 wherein said polymer comprises a methacrylate.
315. A method according to Claim 314 wherein said gas is air.
316. A method according to Claim 278 wherein said polymer comprises a cyanoacrylate.
317. A method according to Claim 316 wherein said gas is air.
318. A method according to Claim 174 wherein said lipid is a phospholipid.
319. A method according to Claim 177 wherein said lipid is a phospholipid.
320. A method according to Claim 181 wherein said lipid is a phospholipid.
321. A method according to Claim 186 wherein said lipid is a phospholipid.
322. A method according to Claim 190 wherein said lipid is a phospholipid.
323. A method according to Claim 196 wherein said lipid is aphospholipid.
324. A method according to Claim 200 wherein said lipid is a phospholipid.
325. A method according to Claim 205 wherein said lipid is a phospholipid.
326. A method according to Claim 209 wherein said lipid is a phospholipid.
327. A method according to Claim 217 wherein said lipid is a phospholipid.
328. A method according to Claim 221 wherein said lipid is a phospholipid.
329. A method according to Claim 226 wherein said lipid is a phospholipid.
330. A method according to Claim 230 wherein said lipid is a phospholipid.
331. A system according to Claim 235 wherein said lipid is a phospholipid.
332. A system according to Claim 238 wherein said lipid is a phospholipid.
333. A system according to Claim 242 wherein said lipid is a phospholipid.
334. A system according to Claim 247 wherein said lipid is a phospholipid.
335. A system according to Claim 251 wherein said lipid is a phospholipid.
336. A method according to Claim 1 wherein said composition is reconstituted from a lyophilized composition.
337. A method according to Claim 2 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
338. A method according to Claim 337 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
339. A method according to Claim 337 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
340. A method according to Claim 14 wherein said gas or gaseous precursor comprises a perfluorocarbon.
341. A method according to Claim 340 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
342. A method according to Claim 341 wherein said perfluorocarbon is perfluoropropane.
343. A method according to Claim 45 wherein said composition is reconstituted from a lyophilized composition.
344. A method according to Claim 45 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
345. A method according to Claim 344 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
346. A method according to Claim 344 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
347. A method according to Claim 60 wherein said composition is reconstituted from a lyophilized composition.
348. A method according to Claim 61 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
349. A method according to Claim 348 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
350. A method according to Claim 348 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
351. A method according to Claim 69 wherein said gas or gaseous precursor comprises a perfluorocarbon.
352. A method according to Claim 351 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
353. A method according to Claim 352 wherein said perfluorocarbon is perfluoroplopane.
354. A method according to Claim 95 wherein said composition is reconstituted from a lyophilized composition.
355. A method according to Claim 95 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
356. A method according to Claim 355 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
357. A method according to Claim 355 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
358. A method according to Claim 115 wherein said composition is reconstituted from a lyophilized composition.
359. A method according to Claim 116 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
360. A method according to Claim 359 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
361. A method according to Claim 359 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
362. A method according to Claim 128 wherein said gas or gaseous precursor comprises a perfluorocarbon.
363. A method according to Claim 362 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
364. A method according to claim 363 wherein said perfluorocarbon is perfluoropropane.
365. A method according to Claim 157 wherein said composition is reconstituted from a lyophilized composition.
366. A method according to Claim 157 wherein said vesicles comprise lipids and wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
367. A method according to Claim 366 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
368. A method according to Claim 366 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
369. A method according to Claim 157 wherein said vesicles comprise proteins, and wherein said gas or gaseous precursor comprises a perfluorocarbon.
370. A method according to Claim 369 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
371. A method according to Claim 370 wherein said perfluorocarbon is perfluoropropane.
372. A method according to Claim 158 wherein said composition is reconstituted from a lyophilized composition.
373. A method according to Claim 158 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
374. A method according to Claim 373 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
375. A method according to Claim 373 wherein said gas or gaseous precursor is a combination of nitrogen and perfluolopropane.
376. A method according to Claim 159 wherein said composition is reconstituted from a lyophilized composition.
377. A method according to Claim 159 wherein said vesicles comprise lipids and wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
378. A method according to Claim 377 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
379. A method according to Claim 377 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
380. A method according to Claim 159 wherein said vesicles comprise proteins and wherein said gas or gaseous precursor comprises a perfluorocarbon.
381. A method according to Claim 380 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
382. A method according to claim 381 wherein said perfluorocarbon is perfluoropropane.
383. A method according to Claim 160 wherein said composition is reconstituted from a lyophilized composition.
384. A method according to Claim 160 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
385. A method according to Claim 384 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
386. A method according to Claim 384 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
387. A system according to Claim 171 wherein said composition is reconstituted from a lyophilized composition.
388. A system according to Claim 171 wherein said vesicles comprise lipids and wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
389. A system according to Claim 388 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
390. A system according to Claim 388 wherein said gas orgaseous precursor is a combination of nitrogen and perfluoropropane.
391. A system according to Claim 171 wherein said vesicles comprise proteins and wherein said gas or gaseous precursor comprises a perfluorocarbon.
392. A system according to Claim 391 wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
393. A system according to Claim 392 wherein said perfluorocarbon is perfluoropropane.
394. A system according to Claim 172 wherein said composition is reconstituted from a lyophilized composition.
395. A system according to Claim 172 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
396. A system according to Claim 395 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
397. A system according to Claim 395 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
398. A method for providing an image of an intemal region of a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said vesicle composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in the image.
399. A method for providing an image of an intemal region of a patient comprising (i) administering to the patient a composition comprising, in an aqueous carrier, a surfactant and a gas or gaseous precursor, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in the image.
400. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
401. A method for providing an image of an internal region of a patient comprising (i) administering to the patient a composition comprising, in an aqueous carrier, a surfactant and a gas or gaseous precursor, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of the region, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
402. A method according to Claim 110 wherein said contrast agent comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants.
403. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said vesicle composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in said image.
404. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a composition comprising, in an aqueous carrier, a surfactant and a gas or gaseous precursor, and (ii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said composition is administered to the patient at a rate which substantially eliminates diagnostic artifacts in said image.
405. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
406. A method for diagnosing the presence of diseased tissue in a patient comprising (i) administering to the patient à composition comprising, in an aqueous carrier, a surfactant and a gas or gaseous precursor, (ii) flushing said composition, and (iii) scanning the patient using diagnostic imaging to obtain a visible image of any diseased tissue in the patient, wherein said composition is flushed at a rate which substantially eliminates diagnostic artifacts in the image.
407. A system according to Claim 161 wherein said contrast agent comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising surfactants.
408. A method according to Claim 398 wherein said composition is reconstituted from a lyophilized composition.
409. A method according to Claim 398 wherein said gas or gaseous precursor is selected from the group consisting of nitrogen, sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, perfluoroheptane, perfluorooctane and perfluorononane.
410. A method according to Claim 409 wherein said gas or gaseous precursor is a combination of nitrogen and perfluorohexane.
411. A method according to Claim 409 wherein said gas or gaseous precursor is a combination of nitrogen and perfluoropropane.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/666,129 US6033645A (en) | 1996-06-19 | 1996-06-19 | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US08/666,129 | 1996-06-24 | ||
PCT/US1997/010510 WO1997048337A1 (en) | 1996-06-19 | 1997-06-16 | Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2256592A1 true CA2256592A1 (en) | 1997-12-24 |
CA2256592C CA2256592C (en) | 2010-06-01 |
Family
ID=24672945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2256592A Expired - Lifetime CA2256592C (en) | 1996-06-19 | 1997-06-16 | Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent |
Country Status (9)
Country | Link |
---|---|
US (2) | US6033645A (en) |
EP (1) | EP0930844B8 (en) |
JP (1) | JP2000513357A (en) |
AU (1) | AU733492B2 (en) |
CA (1) | CA2256592C (en) |
DE (1) | DE69738964D1 (en) |
HK (1) | HK1019699A1 (en) |
RU (1) | RU2199348C2 (en) |
WO (1) | WO1997048337A1 (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150539A1 (en) * | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
US6743779B1 (en) * | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
JP2001507207A (en) * | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | Methods for delivering compounds to cells |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US7273458B2 (en) | 1998-01-12 | 2007-09-25 | Georgia Tech Research Corporation | Method of applying acoustic energy effective to alter transport or cell viability |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
DE19811349C1 (en) * | 1998-03-16 | 1999-10-07 | Siemens Ag | Process for contrast substance tracing using medical imaging appts. |
EP1066537A1 (en) | 1998-03-18 | 2001-01-10 | Magnetic Imaging Technologies Inc. | MR METHODS FOR IMAGING PULMONARY AND CARDIAC VASCULATURE AND EVALUATING BLOOD FLOW USING DISSOLVED POLARIZED ?129 Xe |
ATE276745T1 (en) * | 1998-04-09 | 2004-10-15 | Amersham Health As | USE OF PARTICLE CONTRAST AGENTS IN DIAGNOSTIC IMAGING FOR THE INVESTIGATION OF PHYSIOLOGICAL PARAMETERS |
GB2336680A (en) * | 1998-04-25 | 1999-10-27 | Marconi Gec Ltd | Imaging using a contrast agent |
US6286319B1 (en) * | 1998-09-30 | 2001-09-11 | Medi-Physics, Inc. | Meted hyperpolarized noble gas dispensing methods and associated devices |
US6523356B2 (en) | 1998-09-30 | 2003-02-25 | Medi-Physics, Inc. | Meted hyperpolarized noble gas dispensing methods and associated devices |
US6284222B1 (en) | 1998-11-03 | 2001-09-04 | Medi--Physics, Inc. | Hyperpolarized helium-3 microbubble gas entrapment methods |
US6554792B2 (en) | 1999-05-21 | 2003-04-29 | Mallinckrodt Inc. | Suspension device and method |
GB9920392D0 (en) * | 1999-08-27 | 1999-11-03 | Nycomed Imaging As | Improvemets in or relating to diagnostic imaging |
US9040078B2 (en) | 2000-01-10 | 2015-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases of the nervous system |
US7893226B2 (en) | 2004-09-29 | 2011-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
US8076312B2 (en) | 2000-01-10 | 2011-12-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Use of lipid conjugates in the treatment of disease |
US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US7772196B2 (en) | 2000-01-10 | 2010-08-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
US8916539B2 (en) | 2000-01-10 | 2014-12-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
US8501701B2 (en) | 2000-01-10 | 2013-08-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
US8304395B2 (en) | 2000-01-10 | 2012-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Lipid conjugates in the treatment of disease |
US7608598B2 (en) | 2000-01-10 | 2009-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of conjunctivitis |
US7811999B2 (en) | 2000-01-10 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Use of lipid conjugates in the treatment of diseases |
MXPA02008361A (en) * | 2000-02-28 | 2004-05-17 | Genesegues Inc | Nanocapsule encapsulation system and method. |
WO2001067955A2 (en) * | 2000-03-13 | 2001-09-20 | Medi-Physics, Inc. | Diagnostic procedures using direct injection of gaseous hyperpolarized 129xe and associated systems and products |
US7214223B2 (en) * | 2000-03-24 | 2007-05-08 | Boston Scientific Scimed, Inc. | Photoatherolytic catheter apparatus and method |
WO2002000298A1 (en) * | 2000-06-28 | 2002-01-03 | Insightec - Image Guided Treatment, Ltd. | Use of temperature sensitive liposomes |
WO2002005709A2 (en) * | 2000-07-13 | 2002-01-24 | Medi-Physics, Inc. | Diagnostic procedures using 129xe spectroscopy characteristic chemical shift to detect pathology in vivo |
US7311893B2 (en) * | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
US7045283B2 (en) * | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US8883761B2 (en) | 2001-01-10 | 2014-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases associated with vasculature |
GB0110392D0 (en) * | 2001-04-27 | 2001-06-20 | Oxford Instr Plc | Method and apparatus for magnetic resonance imaging |
US20030044354A1 (en) * | 2001-08-16 | 2003-03-06 | Carpenter Alan P. | Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release |
US7179450B2 (en) * | 2001-09-20 | 2007-02-20 | Medi-Physics, Inc. | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
US7666979B2 (en) * | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
US7985402B2 (en) * | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
CA2513044A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) * | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7211240B2 (en) * | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) * | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
KR100834480B1 (en) * | 2002-04-19 | 2008-06-09 | 주식회사 엘지생활건강 | Vesicles with high anti-bacterial activity |
WO2003094710A2 (en) * | 2002-05-09 | 2003-11-20 | Ultrast Llc | Medium for contrast enhancement use for ultrasonic, endoscopic and other medical examinations |
US6836528B2 (en) * | 2002-07-23 | 2004-12-28 | Ge Medical Systems Global Technology Company, Llc | Methods and apparatus for detecting structural, perfusion, and functional abnormalities |
US7792568B2 (en) * | 2003-03-17 | 2010-09-07 | Boston Scientific Scimed, Inc. | MRI-visible medical devices |
US20040258760A1 (en) * | 2003-03-20 | 2004-12-23 | Wheatley Margaret A. | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production |
US7713517B2 (en) * | 2004-04-21 | 2010-05-11 | Marval Biosciences, Inc. | Compositions and methods for enhancing contrast in imaging |
US8357351B2 (en) | 2004-04-21 | 2013-01-22 | Ananth Annapragada | Nano-scale contrast agents and methods of use |
JP5597342B2 (en) * | 2004-04-29 | 2014-10-01 | コーニンクレッカ フィリップス エヌ ヴェ | Magnetic resonance imaging at several RF frequencies |
US7042219B2 (en) * | 2004-08-12 | 2006-05-09 | Esaote S.P.A. | Method for determining the condition of an object by magnetic resonance imaging |
WO2006027738A1 (en) | 2004-09-10 | 2006-03-16 | Philips Intellectual Property & Standards Gmbh | Compounds and methods for combined optical-ultrasound imaging |
US7643864B2 (en) * | 2005-02-03 | 2010-01-05 | Case Western Reserve University | Adaptive imaging parameters with MRI |
WO2006090298A1 (en) * | 2005-02-23 | 2006-08-31 | Philips Intellectual Property & Standards Gmbh | Imaging an object of interest |
US8906882B2 (en) | 2005-11-17 | 2014-12-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of allergic rhinitis |
US8859524B2 (en) | 2005-11-17 | 2014-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of chronic rhinosinusitis |
US20070140973A1 (en) * | 2005-12-15 | 2007-06-21 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardium perfusion imaging |
US20090238883A1 (en) * | 2006-04-28 | 2009-09-24 | Kren Betsy T | Liver-specific nanocapsules and methods of using |
WO2007136554A1 (en) * | 2006-05-15 | 2007-11-29 | Mayo Foundation For Medical Education And Research | Method for imaging intracavitary blood flow patterns |
AU2007272373B2 (en) * | 2006-07-13 | 2011-10-27 | The Regents Of The University Of Colorado | Echo particle image velocity (EPIV) and echo particle tracking velocimetry (EPTV) system and method |
EP2053974A2 (en) | 2006-08-08 | 2009-05-06 | Keter Medical Ltd. | Imaging system |
CA2705785A1 (en) | 2006-11-14 | 2008-05-22 | Saul Yedgar | Use of lipid conjugates in the treatment of diseases or disorders of the eye |
CN101951835B (en) * | 2007-12-05 | 2015-02-11 | 马维尔生物科学公司 | Nano-scale contrast agents and methods of use |
US8763410B2 (en) * | 2008-04-21 | 2014-07-01 | General Electric Company | Method and apparatus for the dissolution and filtration of a hyperpolarized agent with a neutral dissolution media |
WO2009152445A1 (en) * | 2008-06-13 | 2009-12-17 | Marval Biosciences, Inc. | Imaging of atherosclerotic plaques using liposomal imaging agents |
US10143455B2 (en) | 2011-07-20 | 2018-12-04 | Covidien LLP | Enhanced ultrasound visualization of intravascular devices |
CA2753207C (en) | 2009-02-20 | 2017-07-11 | Sapheon, Inc. | Methods and devices for venous occlusion for the treatment of venous insufficiency |
CA2761590C (en) | 2009-05-11 | 2018-08-28 | Morria Biopharmaceuticals | Lipid-polymer conjugates, their preparation and uses thereof |
WO2011029094A2 (en) | 2009-09-04 | 2011-03-10 | The University Of North Carolina At Chapel Hill | Systems, methods, and computer readable media for high- frequency contrast imaging and image-guided therapeutics |
US9427410B2 (en) | 2010-10-08 | 2016-08-30 | The University Of North Carolina At Chapel Hill | Formulation of acoustically activatable particles having low vaporization energy and methods for using same |
US8808620B1 (en) | 2012-02-22 | 2014-08-19 | Sapheon, Inc. | Sterilization process design for a medical adhesive |
WO2014055832A1 (en) | 2012-10-04 | 2014-04-10 | The University Of North Carolina At Chapel Hill | Methods and systems for using encapsulated microbubbles to process biological samples |
SG10201902499VA (en) | 2014-09-03 | 2019-04-29 | Genesegues Inc | Therapeutic nanoparticles and related compositions, methods and systems |
CA2972423A1 (en) | 2014-12-31 | 2016-07-07 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
KR20180133527A (en) | 2016-05-04 | 2018-12-14 | 랜티우스 메디컬 이메징, 인크. | Method and apparatus for producing ultrasound contrast agent |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
WO2022235830A1 (en) * | 2021-05-05 | 2022-11-10 | The Regents Of The University Of California | Low x-ray attenuation change hard shelled oral contrast material |
Family Cites Families (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3015128A (en) * | 1960-08-18 | 1962-01-02 | Southwest Res Inst | Encapsulating apparatus |
NL302030A (en) | 1962-12-21 | 1900-01-01 | ||
US3291843A (en) * | 1963-10-08 | 1966-12-13 | Du Pont | Fluorinated vinyl ethers and their preparation |
BE661981A (en) * | 1964-04-03 | |||
US3594326A (en) * | 1964-12-03 | 1971-07-20 | Ncr Co | Method of making microscopic capsules |
US3968203A (en) * | 1965-10-01 | 1976-07-06 | Jerome G. Spitzer | Aerosol astringent composition |
DE1626358B1 (en) * | 1965-12-08 | 1971-04-29 | Basf Ag | PARALLEL FLOW GAS BURNER |
US3401475A (en) * | 1966-07-18 | 1968-09-17 | Dow Chemical Co | Label and labelled container |
US3488714A (en) * | 1966-09-19 | 1970-01-06 | Dow Chemical Co | Formed laminate structure and method of preparation |
US3615972A (en) * | 1967-04-28 | 1971-10-26 | Dow Chemical Co | Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same |
US3557294A (en) * | 1967-10-12 | 1971-01-19 | Allied Chem | Fluorinated ethers as inhalation convulsants |
US3479811A (en) * | 1967-11-29 | 1969-11-25 | Dow Chemical Co | Yarn and method of making the same |
US3732172A (en) * | 1968-02-28 | 1973-05-08 | Ncr Co | Process for making minute capsules and prefabricated system useful therein |
US3650831A (en) * | 1969-03-10 | 1972-03-21 | Armour Dial Inc | Method of cleaning surfaces |
US4027007A (en) * | 1970-12-09 | 1977-05-31 | Colgate-Palmolive Company | Antiperspirants formulated with borax |
US3873564A (en) * | 1971-03-03 | 1975-03-25 | Synvar Ass | 2-Imidazolinyl-3-oxide-1-oxypropionic acid |
US4108806A (en) * | 1971-12-06 | 1978-08-22 | The Dow Chemical Company | Thermoplastic expandable microsphere process and product |
US4179546A (en) * | 1972-08-28 | 1979-12-18 | The Dow Chemical Company | Method for expanding microspheres and expandable composition |
CH588887A5 (en) * | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
US3945956A (en) * | 1975-06-23 | 1976-03-23 | The Dow Chemical Company | Polymerization of styrene acrylonitrile expandable microspheres |
GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
US4162282A (en) * | 1976-04-22 | 1979-07-24 | Coulter Electronics, Inc. | Method for producing uniform particles |
GB1599881A (en) * | 1977-02-02 | 1981-10-07 | Millington A R | Preparation for diagnostic radiology |
CH621479A5 (en) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
CH624011A5 (en) * | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
US4310506A (en) * | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4310505A (en) * | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
US4342826A (en) * | 1980-02-04 | 1982-08-03 | Collaborative Research, Inc. | Immunoassay products and methods |
US4421562A (en) * | 1980-04-13 | 1983-12-20 | Pq Corporation | Manufacturing process for hollow microspheres |
US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4315514A (en) * | 1980-05-08 | 1982-02-16 | William Drewes | Method and apparatus for selective cell destruction |
US4331654A (en) * | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
US4442843A (en) * | 1980-11-17 | 1984-04-17 | Schering, Ag | Microbubble precursors and methods for their production and use |
US4657756A (en) * | 1980-11-17 | 1987-04-14 | Schering Aktiengesellschaft | Microbubble precursors and apparatus for their production and use |
US4681119A (en) * | 1980-11-17 | 1987-07-21 | Schering Aktiengesellschaft | Method of production and use of microbubble precursors |
CA1170569A (en) | 1980-11-17 | 1984-07-10 | Julia S. Rasor | Microbubble precursors and methods for their production and use |
US4420442A (en) * | 1981-04-13 | 1983-12-13 | Pq Corporation | Manufacturing process for hollow microspheres |
US4533254A (en) * | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
EP0068961A3 (en) * | 1981-06-26 | 1983-02-02 | Thomson-Csf | Apparatus for the local heating of biological tissue |
US4534899A (en) * | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4426330A (en) * | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4569836A (en) * | 1981-08-27 | 1986-02-11 | Gordon Robert T | Cancer treatment by intracellular hyperthermia |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
US4540629A (en) * | 1982-04-08 | 1985-09-10 | Pq Corporation | Hollow microspheres with organosilicon-silicate walls |
DE3225848A1 (en) * | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | PREPARATION OF CORTICOIDS FOR TOPICAL APPLICATION |
US4532500A (en) * | 1982-09-02 | 1985-07-30 | Pako Corporation | Web tension and break sensor system for photosensitive web processors |
JPS58501576A (en) * | 1982-09-22 | 1983-09-22 | エム.ビイ−.フイラ−ズ プテイ.リミテツド | Material, hollow bilayer silicate microspheres |
FR2534487B1 (en) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY |
DE3374522D1 (en) * | 1982-10-26 | 1987-12-23 | University Of Aberdeen | |
US4603044A (en) * | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4731239A (en) * | 1983-01-10 | 1988-03-15 | Gordon Robert T | Method for enhancing NMR imaging; and diagnostic use |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
US4775522A (en) * | 1983-03-04 | 1988-10-04 | Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center | NMR compositions for indirectly detecting a dissolved gas in an animal |
US4981692A (en) * | 1983-03-24 | 1991-01-01 | The Liposome Company, Inc. | Therapeutic treatment by intramammary infusion |
US5141738A (en) | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
US4615879A (en) * | 1983-11-14 | 1986-10-07 | Vanderbilt University | Particulate NMR contrast agents for gastrointestinal application |
FR2563725B1 (en) * | 1984-05-03 | 1988-07-15 | Dory Jacques | APPARATUS FOR EXAMINING AND LOCATING ULTRASONIC TUMORS WITH A LOCALIZED HYPERTHERMAL TREATMENT DEVICE |
DE3585967D1 (en) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | LIPOSOME FORMING COMPOSITION. |
GB8407557D0 (en) * | 1984-03-23 | 1984-05-02 | Hayward J A | Polymeric lipsomes |
CH668554A5 (en) * | 1984-04-09 | 1989-01-13 | Sandoz Ag | LIPOSOMAS CONTAIN WHICH POLYPEPTIDES WITH INTERLEUKIN-2 ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF. |
US4728575A (en) * | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
US5008109A (en) * | 1984-05-25 | 1991-04-16 | Vestar, Inc. | Vesicle stabilization |
US5008050A (en) * | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4620546A (en) * | 1984-06-30 | 1986-11-04 | Kabushiki Kaisha Toshiba | Ultrasound hyperthermia apparatus |
SE8403905D0 (en) * | 1984-07-30 | 1984-07-30 | Draco Ab | LIPOSOMES AND STEROID ESTERS |
US4921706A (en) * | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
US4689986A (en) * | 1985-03-13 | 1987-09-01 | The University Of Michigan | Variable frequency gas-bubble-manipulating apparatus and method |
US5186922A (en) | 1985-03-15 | 1993-02-16 | See/Shell Biotechnology, Inc. | Use of biodegradable microspheres labeled with imaging energy constrast materials |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
JPS63500175A (en) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−,インコ−ポレイテツド | Liposome inhalation method and inhalation system |
EP0216730B1 (en) | 1985-08-12 | 1991-01-23 | Battelle Memorial Institute | Porous spherical glass filtrating beads and method for the manufacturing thereof |
US4684479A (en) * | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
US4938947A (en) * | 1985-11-01 | 1990-07-03 | Centre National De La Recherche Scientifique (Cnrs) | Aerosol composition for in vivo imaging |
US4927623A (en) * | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
US4987154A (en) * | 1986-01-14 | 1991-01-22 | Alliance Pharmaceutical Corp. | Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use |
US4865836A (en) * | 1986-01-14 | 1989-09-12 | Fluoromed Pharmaceutical, Inc. | Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport |
ES2054658T3 (en) | 1986-01-24 | 1994-08-16 | Childrens Hosp Medical Center | METHOD FOR THE PREPARATION OF A PHYSIOLOGICALLY ACCEPTABLE EMULSION. |
US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4834964A (en) * | 1986-03-07 | 1989-05-30 | M.R.I., Inc. | Use of charged nitroxides as NMR image enhancing agents for CSF |
JPH0751496B2 (en) * | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | Manufacturing method of liposome |
DE3614657A1 (en) | 1986-04-30 | 1987-11-05 | Dornier Medizintechnik | LIPID VESICLES CONTAINING PHARMAKA, METHOD FOR THE PRODUCTION AND INTRODUCTION THEREOF IN THE BODY OF A LIVING BEING AND RELEASE OF THE PHARMACA CONTAINING IN THE LIPID VESICLES |
IL79559A0 (en) | 1986-07-29 | 1986-10-31 | Univ Ramot | Contrast agents for nmr medical imaging |
US4728578A (en) * | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
US4776991A (en) * | 1986-08-29 | 1988-10-11 | The United States Of America As Represented By The Secretary Of The Navy | Scaled-up production of liposome-encapsulated hemoglobin |
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
US4769241A (en) * | 1986-09-23 | 1988-09-06 | Alpha Therapeutic Corporation | Apparatus and process for oxygenation of liquid state dissolved oxygen-carrying formulation |
ZW11287A1 (en) * | 1986-11-04 | 1989-01-25 | Aeci Ltd | Process for the production of an explosive |
DE3637926C1 (en) | 1986-11-05 | 1987-11-26 | Schering Ag | Ultrasonic manometry in a liquid using microbubbles |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US4863717A (en) * | 1986-11-10 | 1989-09-05 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging |
US4933121A (en) * | 1986-12-10 | 1990-06-12 | Ciba Corning Diagnostics Corp. | Process for forming liposomes |
DK175531B1 (en) | 1986-12-15 | 2004-11-22 | Nexstar Pharmaceuticals Inc | Delivery vehicle with amphiphil-associated active ingredient |
CA1321048C (en) * | 1987-03-05 | 1993-08-10 | Robert W. J. Lencki | Microspheres and method of producing same |
US5219538A (en) | 1987-03-13 | 1993-06-15 | Micro-Pak, Inc. | Gas and oxygen carrying lipid vesicles |
US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
EP0296833B1 (en) * | 1987-06-23 | 1991-09-25 | Hafslund Nycomed Innovation AB | Improvements in and relating to magnetic resonance imaging |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
IE61591B1 (en) | 1987-12-29 | 1994-11-16 | Molecular Biosystems Inc | Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production |
US5425366A (en) | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
KR0133132B1 (en) | 1988-02-05 | 1998-04-17 | 쉐링 아게, 베를린 운트 베르크카멘 | Ultrasonic contrast agents, process for producing them and their use as diagnostics |
US4898734A (en) * | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
DE3812816A1 (en) | 1988-04-16 | 1989-11-02 | Lawaczeck Ruediger Dipl Phys P | METHOD FOR SOLUBILIZING LIPOSOMES AND / OR BIOLOGICAL MEMBRANES AND THE USE THEREOF |
US5171755A (en) | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
US4893624A (en) * | 1988-06-21 | 1990-01-16 | Massachusetts Institute Of Technology | Diffuse focus ultrasound hyperthermia system |
US4993415A (en) * | 1988-08-19 | 1991-02-19 | Alliance Pharmaceutical Corp. | Magnetic resonance imaging with perfluorocarbon hydrides |
US4996041A (en) * | 1988-08-19 | 1991-02-26 | Toshiyuki Arai | Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system |
DE3828905A1 (en) | 1988-08-23 | 1990-03-15 | Schering Ag | MEDIALLY COMPOSED OF CAVITATE OR CLATHRATE MAKING HOST / GUEST COMPLEX AS A CONTRAST |
US5045304A (en) * | 1988-08-31 | 1991-09-03 | Wayne State University | Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same |
US5410516A (en) | 1988-09-01 | 1995-04-25 | Schering Aktiengesellschaft | Ultrasonic processes and circuits for performing them |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
FR2637182B1 (en) | 1988-10-03 | 1992-11-06 | Lvmh Rech | COMPOSITIONS BASED ON HYDRATED LIPID LAMID PHASES OR LIPOSOMES CONTAINING AN ECDYSTEROID, PREFERABLY ECDYSTERONE, OR A DERIVATIVE THEREOF; AND COSMETIC, PHARMACEUTICAL, ESPECIALLY DERMATOLOGICAL, SERICULTURE OR PHYTOSANITARY COMPOSITIONS INCORPORATING THE SAME |
US5114703A (en) | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
EP0478686B1 (en) | 1989-06-22 | 1993-08-11 | Applications Et Transferts De Technologies Avancees Atta | Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties |
US5194266A (en) | 1989-08-08 | 1993-03-16 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition and method |
US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5334381A (en) | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US6551576B1 (en) * | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5352435A (en) | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5209720A (en) | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5230882A (en) | 1989-12-22 | 1993-07-27 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5149319A (en) | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5228446A (en) | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US6146657A (en) * | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5123414A (en) | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IN172208B (en) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5556610A (en) | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
US5672585A (en) | 1990-04-06 | 1997-09-30 | La Jolla Cancer Research Foundation | Method and composition for treating thrombosis |
US5368840A (en) | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
US5137928A (en) | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
US5205287A (en) | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
US5190982A (en) | 1990-04-26 | 1993-03-02 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
AU636481B2 (en) | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5196348A (en) | 1990-06-11 | 1993-03-23 | Air Products And Chemicals, Inc. | Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue |
US5315997A (en) | 1990-06-19 | 1994-05-31 | Molecular Biosystems, Inc. | Method of magnetic resonance imaging using diamagnetic contrast |
US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
IL95743A (en) | 1990-09-19 | 1993-02-21 | Univ Ramot | Method of measuring blood flow |
US5487390A (en) | 1990-10-05 | 1996-01-30 | Massachusetts Institute Of Technology | Gas-filled polymeric microbubbles for ultrasound imaging |
US5310540A (en) | 1990-10-05 | 1994-05-10 | Sintetica Sa | Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography |
US5107842A (en) * | 1991-02-22 | 1992-04-28 | Molecular Biosystems, Inc. | Method of ultrasound imaging of the gastrointestinal tract |
DE69215722T3 (en) | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
GB9106673D0 (en) | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
GB9106686D0 (en) | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5496535A (en) | 1991-04-12 | 1996-03-05 | Alliance Pharmaceutical Corp. | Fluorocarbon contrast media for use with MRI and radiographic imaging |
US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
WO1992021382A1 (en) | 1991-06-03 | 1992-12-10 | Holmes, Michael, John | Improvements in or relating to contrast agents |
US5409688A (en) | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
US5362477A (en) | 1991-10-25 | 1994-11-08 | Mallinckrodt Medical, Inc. | 19F magnetic resonance imaging agents which include a nitroxide moiety |
US5196183A (en) | 1991-12-04 | 1993-03-23 | Sterling Winthrop Inc. | Contrast agents for ultrasound imaging |
GB9200388D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
GB9200387D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
JP3325300B2 (en) | 1992-02-28 | 2002-09-17 | 株式会社東芝 | Ultrasound therapy equipment |
US5247935A (en) | 1992-03-19 | 1993-09-28 | General Electric Company | Magnetic resonance guided focussed ultrasound surgery |
US5339814A (en) | 1992-04-14 | 1994-08-23 | Lasker Sigmund E | Process for visualizing tissue metabolism using oxygen-17 |
US5846516A (en) | 1992-06-03 | 1998-12-08 | Alliance Pharmaceutial Corp. | Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications |
DE4221256C2 (en) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenic composition for topical use |
US5552155A (en) | 1992-12-04 | 1996-09-03 | The Liposome Company, Inc. | Fusogenic lipsomes and methods for making and using same |
US5558855A (en) | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
CN1068230C (en) | 1993-01-25 | 2001-07-11 | 索纳斯药品有限公司 | Phase shift colloids as ultrasound contrast agents |
FR2700952B1 (en) | 1993-01-29 | 1995-03-17 | Oreal | New cosmetic or dermopharmaceutical compositions in the form of aqueous gels modified by the addition of expanded microspheres. |
BR9405798A (en) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Methods for in vivo release of biological material and useful compositions thereof |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5716597A (en) | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
US5855865A (en) | 1993-07-02 | 1999-01-05 | Molecular Biosystems, Inc. | Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas |
KR100218642B1 (en) | 1993-07-02 | 1999-09-01 | 스티븐 로손 | Method of making microspheres encapsulated from the temperature-denaturated protein |
EP0711179B2 (en) | 1993-07-30 | 2010-09-01 | IMCOR Pharmaceutical Co. | Stabilized microbubble compositions for ultrasound |
US5798091A (en) * | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
US5433204A (en) | 1993-11-16 | 1995-07-18 | Camilla Olson | Method of assessing placentation |
ATE219688T1 (en) | 1994-03-28 | 2002-07-15 | Nycomed Imaging As | LIPOSOMES CONTAINING AN X-RAY OR ULTRASONIC CONTRAST AGENT |
US5545396A (en) | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
AU2432795A (en) | 1994-05-03 | 1995-11-29 | Molecular Biosystems, Inc. | Composition for ultrasonically quantitating myocardial perfusion |
US5502094A (en) | 1994-05-20 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use |
US5562893A (en) | 1994-08-02 | 1996-10-08 | Molecular Biosystems, Inc. | Gas-filled microspheres with fluorine-containing shells |
US6113570A (en) * | 1994-09-09 | 2000-09-05 | Coraje, Inc. | Method of removing thrombosis in fistulae |
US5540909A (en) | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5560364A (en) | 1995-05-12 | 1996-10-01 | The Board Of Regents Of The University Of Nebraska | Suspended ultra-sound induced microbubble cavitation imaging |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6139819A (en) * | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6521211B1 (en) * | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6231834B1 (en) * | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US5733024A (en) * | 1995-09-13 | 1998-03-31 | Silicon Valley Group, Inc. | Modular system |
US5840023A (en) | 1996-01-31 | 1998-11-24 | Oraevsky; Alexander A. | Optoacoustic imaging for medical diagnosis |
US6414139B1 (en) * | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
CA2263568C (en) * | 1996-09-11 | 2008-12-02 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a contrast agent and a renal vasodilator |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US6331289B1 (en) * | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6548047B1 (en) * | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US6398772B1 (en) * | 1999-03-26 | 2002-06-04 | Coraje, Inc. | Method and apparatus for emergency treatment of patients experiencing a thrombotic vascular occlusion |
US6635017B1 (en) * | 2000-02-09 | 2003-10-21 | Spentech, Inc. | Method and apparatus combining diagnostic ultrasound with therapeutic ultrasound to enhance thrombolysis |
-
1996
- 1996-06-19 US US08/666,129 patent/US6033645A/en not_active Expired - Lifetime
-
1997
- 1997-06-16 WO PCT/US1997/010510 patent/WO1997048337A1/en active Application Filing
- 1997-06-16 CA CA2256592A patent/CA2256592C/en not_active Expired - Lifetime
- 1997-06-16 AU AU33131/97A patent/AU733492B2/en not_active Expired
- 1997-06-16 EP EP97928998A patent/EP0930844B8/en not_active Expired - Lifetime
- 1997-06-16 DE DE69738964T patent/DE69738964D1/en not_active Expired - Lifetime
- 1997-06-16 JP JP10503263A patent/JP2000513357A/en not_active Ceased
- 1997-06-17 RU RU99101052/14A patent/RU2199348C2/en not_active IP Right Cessation
-
1999
- 1999-10-27 HK HK99104828.2A patent/HK1019699A1/en not_active IP Right Cessation
-
2002
- 2002-08-06 US US10/213,533 patent/US20030012735A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2199348C2 (en) | 2003-02-27 |
EP0930844A1 (en) | 1999-07-28 |
WO1997048337A1 (en) | 1997-12-24 |
HK1019699A1 (en) | 2000-02-25 |
US20030012735A1 (en) | 2003-01-16 |
EP0930844B1 (en) | 2008-09-03 |
AU3313197A (en) | 1998-01-07 |
AU733492B2 (en) | 2001-05-17 |
CA2256592C (en) | 2010-06-01 |
EP0930844B8 (en) | 2008-11-26 |
JP2000513357A (en) | 2000-10-10 |
DE69738964D1 (en) | 2008-10-16 |
EP0930844A4 (en) | 2002-03-13 |
US6033645A (en) | 2000-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2256592A1 (en) | Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent | |
Uchegbu et al. | Non-ionic surfactant based vesicles (niosomes) in drug delivery | |
JP5513708B2 (en) | Gas-filled microvesicle assembly for contrast imaging | |
Klibanov | Ultrasound contrast agents: development of the field and current status | |
US7005120B2 (en) | Osmotically stabilized microbubble preparations | |
JP2948246B2 (en) | Liposomes | |
US7087212B2 (en) | Multicomponent assemblies having enhanced binding properties for diagnosis and therapy | |
JP2001514615A (en) | Delivery method for bioactive agents | |
US20030044354A1 (en) | Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release | |
CN1897978B (en) | Assembly of gas-filled microvesicle with active component for contrast imaging | |
JPH11508871A (en) | Novel composition of lipids and stabilizing substances | |
AU4922196A (en) | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement | |
WO2005020918A2 (en) | Ultrasonic concentration of drug delivery capsules | |
EP2253308A1 (en) | Pharmaceutical composition comprising microbubbles for targeted tumor therapy | |
EP0871498B1 (en) | Insoluble gas-filled microspheres containing a hydrophobic barrier | |
US10688199B2 (en) | Theranostic bubble preparation (TB), and method for using same | |
EP1796734A1 (en) | Contrast agent formulations for the visualization of the lymphatic system | |
US20050058697A1 (en) | Cell penetrating therapeutic agents | |
WO2019198461A1 (en) | Contrast agent capable of both ultrasound contrast and near infrared fluorescence contrast | |
JP4595319B2 (en) | Liposomes for liposomes, liposomes and methods for producing them | |
JP2018197208A (en) | Nitrogen monoxide-containing bubble liposome, and use of the same | |
US20030206862A1 (en) | Contrast medium based on polyoxyethylene-660-12-hydroxystearate and anionic phospholipids | |
AU774666B2 (en) | Improved methods for diagnostic imaging by regulating the administration rate of a contrast agent | |
WO1998023298A1 (en) | Perfluorinated-ether compositions as diagnostic contrast agents | |
Lukáč | Micro and Nanoparticles as Drug Carriers: Surface-Modified Microbubbles Used as Ultrasound Contrast Agents and Drug Carriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170616 |